Castrillo Sanz A, Morollón Sánchez-Mateos N, Simonet Hernández C, Fernández Rodríguez B, Cerdán Santacruz D, Mendoza Rodríguez A, Rodríguez Sanz M F, Tabernero García C, Guerrero Becerra P, Ferrero Ros M, Duate García-Luis J
Sección de Neurología, Complejo Hospitalario de Segovia, Segovia, España.
Sección de Neurología, Complejo Hospitalario de Segovia, Segovia, España.
Neurologia (Engl Ed). 2018 Oct;33(8):499-504. doi: 10.1016/j.nrl.2016.09.004. Epub 2016 Oct 21.
The purposes of this study were to describe our 16-month experience with onabotulinumtoxinA (OnabotA) for the treatment of chronic migraine (CM) in the Spanish province of Segovia, evaluate its benefits, and determine clinical markers of good response to treatment.
Prospective study of patients with CM who received OnabotA for 16 months. The effectiveness of OnabotA was evaluated based on the reduction in the number of headache days, pain intensity, and side effects. We used two-way analysis of variance (ANOVA) to assess the effects of treatment according to the time factor. We studied the correlation between treatment effects and other variables using a linear regression model to establish the clinical markers of good response to treatment.
We included 69 patients who met the diagnostic criteria for CM. Patients underwent an average of 2 infiltrations. Mean age was 43 years; 88.4% were women. The number of headache days and pain intensity decreased significantly (P < .005); improvements remained over time. We found a negative correlation between the reduction in pain intensity and the number of treatments before OnabotA.
The beneficial effects of OnabotA for CM continue over time. OnabotA is a safe and well-tolerated treatment whose use for refractory CM should not be delayed since early treatment provides greater benefits.
本研究旨在描述我们在西班牙塞哥维亚省使用A型肉毒毒素（OnabotA）治疗慢性偏头痛（CM）16个月的经验，评估其疗效，并确定治疗良好反应的临床标志物。
对接受OnabotA治疗16个月的CM患者进行前瞻性研究。根据头痛天数、疼痛强度和副作用的减少情况评估OnabotA的有效性。我们使用双向方差分析（ANOVA）根据时间因素评估治疗效果。我们使用线性回归模型研究治疗效果与其他变量之间的相关性，以建立治疗良好反应的临床标志物。
我们纳入了69例符合CM诊断标准的患者。患者平均接受了2次注射。平均年龄为43岁；88.4%为女性。头痛天数和疼痛强度显著减少（P <.005）；随着时间的推移改善持续存在。我们发现疼痛强度的降低与OnabotA治疗前的治疗次数之间存在负相关。
OnabotA对CM的有益作用会随着时间持续存在。OnabotA是一种安全且耐受性良好的治疗方法，对于难治性CM的使用不应延迟，因为早期治疗会带来更大的益处。
